BioWorld

Feb. 24, 2003

Monitoring Committee Suspends Enrollment In QLT, Xenova Trial

QLT Inc. agreed to temporarily suspend enrollment in two Phase III studies of tariquidar in non-small-cell lung cancer patients on advice of a monitoring committee, which reportedly noted some toxicity in the study. (BioWorld Today) Read More

BioMarin Raises $75M Publicly, Gets Good News On Aldurazyme

Two Interleukin Molecules, IL-12 & IL-23, Duke It Out To Nail Guilt Or Innocence In Mouse Autoimmunity

Nasdaq Market Looking To Ease Rules For Continued Listing

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...